Solence is a technology company.
Solence has raised $2.0M across 1 funding round.
Solence has raised $2.0M in total across 1 funding round.
# Solence: AI-Driven Digital Therapeutics for PCOS
Solence is a femtech company that develops AI-powered digital therapeutics to address Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting up to 20% of women worldwide.[2] Founded in 2022 by Clara Stephenson, the Paris-based startup creates patient-centric care solutions designed to help women manage PCOS symptoms through personalized lifestyle interventions rather than relying solely on pharmaceutical treatment.[1] The company's flagship product is a mobile app offering a twelve-week program grounded in peer-reviewed research, enabling women to address PCOS "beyond the pill" through tailored digital therapeutics.[2]
Solence addresses a critical gap in women's healthcare: while 85% of women with PCOS lack adequate support, the condition causes significant quality-of-life impacts including weight gain, irregular periods, mental health struggles, and workplace difficulties.[2] The company's mission extends beyond symptom management to increasing healthy life expectancy for women by reducing the burden of chronic conditions through lifestyle-based and AI-powered interventions.[1]
Clara Stephenson founded Solence after a decade-long personal struggle with undiagnosed PCOS during her career as a corporate lawyer at Ernst & Young.[2] Her diagnosis emerged during fertility investigations, which revealed both the long-term condition and potential infertility risks—a pivotal moment that redirected her professional trajectory.[2]
Before launching Solence, Stephenson created Les Natives, a PCOS-focused health and wellness blog born during the COVID pandemic where she shared her personal experiences.[1] The blog gained substantial traction, accumulating over 135,000 visits and building a committed online community of more than 8,000 followers.[1] This organic validation of demand—demonstrating genuine interest in PCOS education and support—provided the foundation for Solence's launch and validated the market opportunity.[1]
Solence operates at the intersection of three significant trends: the femtech movement, the digital therapeutics revolution, and the chronic disease management shift. Women's health has historically been underfunded and under-researched relative to disease prevalence, making femtech startups increasingly attractive to impact-focused investors.[1] The company's €1.6M seed round—backed by Impact Shakers Ventures and notable angels including Céline Lazorthes (founder of Mangopay and Leetchi)—reflects growing capital recognition of women's health as both a social imperative and commercial opportunity.[1]
Solence also exemplifies the broader healthcare trend toward digital-first, preventive care models that reduce reliance on pharmaceutical interventions. As healthcare systems globally grapple with chronic disease burden and medication costs, software-based therapeutic solutions offer scalable alternatives. By targeting PCOS—affecting hundreds of millions of women—Solence addresses a condition with massive addressable market potential and minimal existing digital solutions.[2]
Solence is positioned to become a category leader in digital PCOS care, with immediate priorities focused on deepening app functionality, expanding clinical partnerships, and scaling distribution.[1] The company's success will depend on clinical validation of its AI-driven interventions and ability to integrate with existing healthcare systems to reach the 85% of PCOS patients currently underserved.[2]
Looking forward, Solence's model—combining founder expertise, data-driven personalization, and lifestyle-first treatment—could extend beyond PCOS to other hormone-related and metabolic conditions affecting women. As digital therapeutics gain regulatory acceptance and reimbursement pathways mature, companies like Solence that combine clinical rigor with user-centric design will likely shape the future of chronic disease management. The timing is favorable: investor appetite for femtech is rising, digital health adoption has normalized post-pandemic, and PCOS awareness is growing—creating a convergence that could accelerate Solence's path to impact and scale.
Solence has raised $2.0M in total across 1 funding round.
Solence's investors include Reach Capital, Charles Gorintin, Chris M. Willliams, Jean Charles Samuelian, Karim Atiyeh.
Solence has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $2.0M Seed | Reach Capital, Charles Gorintin, Chris M. Willliams, Jean Charles Samuelian, Karim Atiyeh |